Ironwood Pharmaceuticals, Inc. Appoints Michael Shetzline as Chief Medical Officer, Senior Vice President and Head of Drug Development, Effective January 28, 2019
January 07, 2019 at 03:30 am IST
Share
Ironwood Pharmaceuticals, Inc. announced that Michael Shetzline, M.D., Ph.D., will join Ironwood as chief medical officer, senior vice president and head of drug development, effective January 28, 2019. Dr. Shetzline will lead global product development for Ironwood following its planned separation into two independent, publicly-traded companies. In his role, Dr. Shetzline will focus on driving innovation designed to enhance the value of the company’s existing GI assets and creating new GI product opportunities. He will report to Thomas McCourt, who will become President of Ironwood following the separation.
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.
Ironwood Pharmaceuticals, Inc. Appoints Michael Shetzline as Chief Medical Officer, Senior Vice President and Head of Drug Development, Effective January 28, 2019
IRONWOOD PHARMACEUTICALS, INC. 
